KR20130100918A - Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 - Google Patents

Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 Download PDF

Info

Publication number
KR20130100918A
KR20130100918A KR1020127032811A KR20127032811A KR20130100918A KR 20130100918 A KR20130100918 A KR 20130100918A KR 1020127032811 A KR1020127032811 A KR 1020127032811A KR 20127032811 A KR20127032811 A KR 20127032811A KR 20130100918 A KR20130100918 A KR 20130100918A
Authority
KR
South Korea
Prior art keywords
antibody
seq
ser
lymphoma
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127032811A
Other languages
English (en)
Korean (ko)
Inventor
슈테판 스틸겐바우어
토르슈텐 젠츠
칼-하인츠 하이더
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130100918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20130100918A publication Critical patent/KR20130100918A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127032811A 2010-07-16 2011-07-15 Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능 Ceased KR20130100918A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10169795.1 2010-07-16
EP10169795 2010-07-16
EP10175586 2010-09-07
EP10175586.6 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (1)

Publication Number Publication Date
KR20130100918A true KR20130100918A (ko) 2013-09-12

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127032811A Ceased KR20130100918A (ko) 2010-07-16 2011-07-15 Ｃｌｌ 혈액 샘플에서의 ｃｄ37 항체의 우수한 효능

Country Status (15)

Country Link
US (3) US20120189618A1 (https=)
EP (2) EP2593479A1 (https=)
JP (2) JP2013538790A (https=)
KR (1) KR20130100918A (https=)
CN (2) CN105749276A (https=)
AU (1) AU2011278227B2 (https=)
BR (1) BR112013001012A2 (https=)
CA (1) CA2799036A1 (https=)
CL (1) CL2013000101A1 (https=)
EA (1) EA025365B1 (https=)
IL (1) IL222775A (https=)
MX (1) MX341463B (https=)
NZ (2) NZ603161A (https=)
PH (1) PH12013500118A1 (https=)
WO (1) WO2012007576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
WO2013171287A1 (en) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
EP3283520B1 (en) 2015-04-13 2020-05-06 Pfizer Inc Chimeric antigen receptors targeting b-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
AU2018236450A1 (en) * 2017-03-16 2019-10-03 The General Hospital Corporation Chimeric antigen receptors targeting CD37
EP3601354A1 (en) 2017-03-31 2020-02-05 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
AU2024362226A1 (en) 2023-10-18 2026-03-05 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HRP20140338T1 (hr) * 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2365003A1 (en) * 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения

Also Published As

Publication number Publication date
US20120189618A1 (en) 2012-07-26
JP2017019800A (ja) 2017-01-26
EA201201660A1 (ru) 2013-07-30
CA2799036A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
IL222775A (en) 2017-10-31
EP3252077A1 (en) 2017-12-06
CN103003309A (zh) 2013-03-27
CL2013000101A1 (es) 2013-12-27
NZ603161A (en) 2015-02-27
CN105749276A (zh) 2016-07-13
WO2012007576A1 (en) 2012-01-19
NZ703225A (en) 2016-11-25
US20130236454A1 (en) 2013-09-12
PH12013500118A1 (en) 2013-03-11
EP2593479A1 (en) 2013-05-22
IL222775A0 (en) 2012-12-31
US20150266967A1 (en) 2015-09-24
EA025365B1 (ru) 2016-12-30
MX341463B (es) 2016-08-22
AU2011278227B2 (en) 2017-03-02
BR112013001012A2 (pt) 2016-05-24
AU2011278227A1 (en) 2012-11-15
MX2012013613A (es) 2012-12-17

Similar Documents

Publication Publication Date Title
KR102821932B1 (ko) 항-ccr8 항체 및 이의 용도
AU2011278227B2 (en) Superior efficacy of CD37 antibodies in CLL blood samples
JP6457431B2 (ja) 抗アクチビンａ抗体およびその使用
TWI679021B (zh) 無海藻糖基化抗fgfr2iiib抗體
KR101745230B1 (ko) Pan-ELR+ CXC 케모카인 항체
TW201132353A (en) WISE binding agents and epitopes
JPH11507535A (ja) 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP2010502740A5 (https=)
CN102421802A (zh) 人源化的axl抗体
EP3825330A1 (en) Anti-cd117 antibodies and methods of use thereof
CN119569881B (zh) 抗cd39抗体及其用途
JP7075135B2 (ja) 増殖因子を標的とする二機能性分子を使用したがんの治療方法
WO2007064911A1 (en) Anti-mouse cd20 antibodies and uses thereof
EP3915641A1 (en) Anti-cd5 antibodies and methods of use thereof
EP4377342A1 (en) Humanized anti-human beta ig-h3 protein and uses thereof
CN114787188A (zh) 用抗pd-1抗体治疗癌症的方法
US12077597B2 (en) Anti-CD5 antibodies and methods of use thereof
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
CN117015398A (zh) 治疗炎性皮肤病症的方法
HK40000997B (en) Pan-elr+ cxc chemokine antibodies
HK40000997A (en) Pan-elr+ cxc chemokine antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170918

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170918

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I